PlantForm awarded federal government contract for production of anti-nerve-agent enzyme
GUELPH, Ont., Dec. 10, 2014—PlantForm Corporation has been awarded a contract with the Government of Canada to create stable glyco-modified Nicotiana benthamiana plant lines for the production of pharmaceutical proteins and continued supply of recombinant butyrylcholinesterase (BuChE)
The contract is valued at $831,600 and and the period of the contract is from December 3, 2014 to March 31, 2017.
"Butyrylcholinesterase is an enzyme that has been developed as a bioscavenger to provide prophylactic protection against nerve agents, such as sarin gas," said Dr. Don Stewart, PlantForm President and CEO. "We are pleased to use our vivoXPRESS™ biopharmaceuti
In 2013, PlantForm successfully completed a contract with the U.S. Defense Advanced Research Projects Agency (DARPA) for research and development of recombinant BuChE production in plants.
About PlantForm Corporation
PlantForm was established in 2008 to commercialize a low-cost, tobacco-plant-based manufacturing system for biopharmaceutical production. The vivoXPRESS™ platform
For more information, please contact:
President and CEO
Stacey Curry Gunn
Director of Communications